Outcome of the Board Meeting
BAJAJHCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.1 pts less than Nifty Microcap 250 and 10.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bajaj Healthcare reported FY2026 revenue from operations of Rs 61,103 lakhs, up 12.6% from Rs 54,260 lakhs in FY2025, showing steady top-line growth. However, profit after tax from continuing operations dropped sharply to Rs 2,131 lakhs from Rs 4,293 lakhs — a 50% decline — mainly due to an exceptional charge of Rs 3,325 lakhs arising from reversal of income from a failed technical know-how arrangement with a Middle East customer affected by regional instability. Total PAT including discontinued operations fell to Rs 1,577 lakhs from Rs 3,950 lakhs (down 60%). The board recommended a 30% dividend (Rs 1.50 per share of Rs 5 face value), appointed JCR & Co. LLP as internal auditors for FY2027, and reappointed V.J. Talati & Co. as cost auditors. Statutory auditors Walker Chandiok & Co LLP issued an unmodified opinion. The company also completed conversion of 20.79 lakh convertible warrants into equity shares, raising Rs 5,271 lakhs (balance 75% of issue price), bringing total equity funds raised to Rs 16,226 lakhs.
The large exceptional item reversal has severely compressed FY2026 profits, though underlying operations grew revenue by 12.6%. The dividend recommendation provides some support for shareholders, but the significant PAT decline and uncertain Middle East exposure may weigh on the stock near term.